Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
复制标题
DOI：
10.1038/s41375-018-0094-0
复制
发表时间：
2018-11
期刊：
影响因子：
11.4
通讯作者：
Whitlock JA
中科院分区：
文献类型：
--
作者：
Sun W;Malvar J;Sposto R;Verma A;Wilkes JJ;Dennis R;Heym K;Laetsch TW;Widener M;Rheingold SR;Oesterheld J;Hijiya N;Sulis ML;Huynh V;Place AE;Bittencourt H;Hutchinson R;Messinger Y;Chang B;Matloub Y;Ziegler DS;Gardner R;Cooper T;Ceppi F;Hermiston M;Dalla-Pozza L;Schultz KR;Gaynon P;Wayne AS;Whitlock JA
历史上，患有多次复发和/或难治性 (R/R) B 细胞急性淋巴细胞白血病的儿科患者的生存率非常低；然而，当前的数据有限。我们进行了一项回顾性研究，以确定 2005 年至 2013 年间在 24 家 TACL 机构治疗的多重 R/R 儿童 B-ALL 的结果。收集了患者信息、治疗和反应。分析影响完全缓解（CR）率和无事件生存（EFS）的预后因素。该分析集包括 325 名患者的 578 次挽救治疗尝试。接受第二次挽救尝试的骨髓 R/R B-ALL 患者的 CR 率（平均值±SE）为 51±±4%，第三次尝试为 37±±6%，第四次至第八次尝试合计为 31±±6%。对于在第二次、第三次、第四次至第八次尝试后达到 CR 的患者，2 年 EFS 分别为 41±±6%、13±±7% 和 27±±13%。与之前的研究相比，我们的结果略有改善。这是迄今为止评估该患者群体结果的最大且最新的研究。我们的数据将为正在开发的儿童B-ALL新药的评估提供详细的参考。
The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, and response were collected. Prognostic factors influencing the complete remission (CR) rate and event-free survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (mean ± SE) were 51 ± 4% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 37 ± 6% for a third attempt, and 31 ± 6% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third, and fourth through eighth attempts, the 2 year EFS was 41 ± 6%, 13 ± 7%, and 27 ± 13% respectively. Our results showed slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL.
登录
查看更多内容
影响因子：
45.3
作者：
Tallen, Gesche;Ratei, Richard;von Stackelberg, Arend
通讯作者：
von Stackelberg, Arend
DOI：
10.1056/nejmoa1407222
发表时间：
2014-10-16
期刊：
The New England journal of medicine
影响因子：
--
作者：
Maude SL;Frey N;Shaw PA;Aplenc R;Barrett DM;Bunin NJ;Chew A;Gonzalez VE;Zheng Z;Lacey SF;Mahnke YD;Melenhorst JJ;Rheingold SR;Shen A;Teachey DT;Levine BL;June CH;Porter DL;Grupp SA
通讯作者：
Grupp SA
影响因子：
4.3
作者：
Nemecek, Eneida R.;Ellis, Kristin;Carpenter, Paul A.
通讯作者：
Carpenter, Paul A.
DOI：
10.1126/science.1164266
发表时间：
2008-11-28
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Mullighan CG;Phillips LA;Su X;Ma J;Miller CB;Shurtleff SA;Downing JR
通讯作者：
Downing JR
影响因子：
45.3
作者：
Ko, Richard H.;Ji, Lingyun;Loh, Mignon L.
通讯作者：
Loh, Mignon L.